QPPV.COM KNOWLEDGE ASSESSMENT

Canakinumab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Canakinumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient has a positive tuberculosis screening test before chronic canakinumab therapy, but no evidence of active disease. How should this be interpreted in pharmacovigilance?

It should automatically be counted as drug-induced active tuberculosis It should be distinguished from active or reactivated tuberculosis and assessed using clinical, imaging and microbiological information It should be excluded from all safety records because screening results are never relevant It demonstrates that canakinumab caused a new tuberculosis infection before treatment began

Question 2 of 10 Which feature most strongly supports investigation of a suspected DRESS case rather than treating the report as an isolated rash?

Rash accompanied by eosinophilia, systemic symptoms and internal-organ involvement A brief local injection-site reaction without systemic findings A transient fever immediately after vaccination with no rash An isolated normal liver-test result

Question 3 of 10 Which follow-up dataset is most useful for interpreting a report of canakinumab-associated neutropenia?

Only the date on which the adverse event was entered into the database Baseline and nadir counts, timing, infection status, concomitant medicines, recovery and treatment action Only the patient's final white-cell count The patient's vaccination history without laboratory results

Question 4 of 10 Which information best distinguishes a local injection-site reaction from systemic hypersensitivity to canakinumab?

The patient's age alone Dose number, onset, systemic organ involvement, treatment and recurrence The indication without any event chronology Whether the medicine was supplied in a prefilled syringe

Question 5 of 10 Which mechanistic sequence best explains how IL-1β becomes an active inflammatory mediator?

Mature IL-1β is converted into an inactive precursor by antibodies Pro-IL-1β is processed following innate pathway activation, including inflammasome-associated caspase-1 activity IL-1β is produced only after adaptive lymphocyte depletion Urate crystals directly bind IL-1 receptors without involving cytokine processing

Question 6 of 10 Which statement best describes the regulatory and operational distinction in canakinumab risk management?

Every company follow-up practice is automatically a legal requirement Current product information establishes the regulatory framework, while structured company procedures may enhance case follow-up beyond explicit wording Operational procedures may replace the authorised product information Regulatory wording is unnecessary if a company has a detailed database

Question 7 of 10 What is the most appropriate interpretation of the withdrawal of an application for an additional indication such as Schnitzler syndrome?

The withdrawal automatically invalidates all authorised canakinumab indications The withdrawal shows that the drug has no biological activity against IL-1β The additional indication should not be described as authorised, while existing authorised uses require their own benefit-risk evidence The withdrawal proves that all reported adverse events were caused by the medicine

Question 8 of 10 A patient with Still's disease develops persistent fever, cytopenias, liver dysfunction and hyperferritinaemia. What is the most appropriate pharmacovigilance response?

Code only fever because the other findings are expected in all treated patients Assume infection and close the case without further evaluation Evaluate for macrophage activation syndrome using syndrome-level clinical, laboratory and outcome information Conclude that canakinumab caused MAS because the patient was exposed

Question 9 of 10 A patient with a hereditary periodic fever syndrome develops recurrent symptoms while receiving canakinumab. Which interpretation is most appropriate as an initial pharmacovigilance approach?

The recurrence proves that anti-drug antibodies have eliminated all pharmacological activity The recurrence is necessarily evidence of a new adverse drug reaction The recurrence should be assessed in relation to disease activity, dosing interval, infection, adherence and possible immunogenicity The recurrence proves that the underlying genetic diagnosis was incorrect

Question 10 of 10 Which statement most accurately distinguishes autoinflammation from autoimmunity in the context of canakinumab?

Autoinflammation is primarily driven by dysregulated innate immune signalling, whereas autoimmunity commonly involves adaptive immune recognition Autoinflammation is caused exclusively by antibodies, whereas autoimmunity is caused exclusively by cytokines Autoinflammation does not involve inflammatory cytokines, whereas autoimmunity does Autoinflammation and autoimmunity are interchangeable terms for the same biological process

Canakinumab: Classification, History, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings